Skip to main content

CORRECTED-INSIGHT-US benefits manager baulks after Novartis values gene therapy at $4-5 mln

* At $4-5 mln, SMA treatment would be one of industry's costliest
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.